FDA Fellowship in Model-Informed Drug Development Fellowship

Updated: 2 months ago
Location: Silver Spring, MARYLAND

*Applications will be reviewed on a rolling-basis.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This research covers more than just medicines. The project in the Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), will use model-informed drug development approaches, such as population pharmacokinetic modeling, pharmacokinetic-pharmacodynamic modeling, and clinical trial simulations for regulatory research. Example areas of research include using model-based approaches for characterizing and quantifying effects of immunogenicity on drug exposures and evaluating sensitivity to identify relevant product pharmacokinetic differences across different routes of administration.

Under the guidance of the mentor, the participant will learn model-based approaches, such as pharmacokinetic, pharmacodynamic, and statistical models, and combine them into a prediction framework to evaluate drug efficacy/safety.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

  • Non-employee nature of the ORISE appointment;
  • Prohibition on ORISE Fellows performing inherently governmental functions;
  • Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
  • The fact that research materials and laboratory notebooks are the property of the FDA;
  • ORISE fellow’s obligation to protect and not to further disclose or use non-public information.


The qualified candidate should have received or be currently pursuing a master's or doctoral degree in one of the relevant fields with completion by June 30, 2023. Degree must have been received within the past five years.

Preferred skills:

  • Quantitative modeling or analysis
  • Developing pharmacokinetics/pharmacodynamics models
  • Familiarity with programming languages such as R

To Apply:


View or Apply

Similar Positions